RXRX · Recursion Pharmaceuticals, Inc.
$2.96
-0.05 (-1.66%)
At close · Jul 24
Market Cap
$1.57B
Shares
529.91M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.01
Open$2.93
Day$2.92–3.03
52W$2.77–7.18
Avg vol 30d22.7M
Short int180.8M · 34.1% float · 6.7d
Short vol65%
Last earningsMay 6, 2026
DataApr 2021–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−9%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
5%
near low
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−30%
trailing
YTD return
−26%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
65 of 339 funds reported for Jun 30 · net +41.0K sh shares · +11 new
Insider flow
Distributing
Net -$718.8K over 90 days · 100% sells
Short interest
Rising
34.11% of float · ▲ +4.9% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+27%
Y/Y
EPS growth
+15%
Y/Y
Free cash flow
$-378.3M
Balance sheet
$742.6M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Operational cash burn
· 2026
Initiated
$0 – $390M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
65 of 339 funds reported for Jun 30 · net +41.0K sh shares · +11 new
Insider flow
Distributing
Net -$718.8K over 90 days · 100% sells
Short interest
Rising
34.11% of float · ▲ +4.9% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $3 · 5%
52-wk high $7
vs 200-day avg -24%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Sanofi partnership milestone payments received to date | $134M | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXRX
this stock
Recursion Pharmaceuticals, Inc.
|
$1.57B | -26.4% | +26.9% | — | 34.1% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXRX | -0.3% | -6.8% | -30.3% | -18.0% | -26.4% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +1.3% | -7.5% | -36.7% | -16.8% | -34.7% |
Key facts
CIK
1601830
CUSIP
75629V104
13F (30d)
60 filings
60 filers
Visit website
Investor relations